Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06611891
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2023-04-20
Brief Title:
Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DOTABREAST
Brief Summary:
DOTABREAST Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer
This is a prospective monocentric non-controlled non-randomized open-label interventional study
This is a prospective monocentric non-controlled non-randomized open-label interventional study
Detailed Description:
In women breast cancer is the 1st largest cancer and accounted for 31 of new cancer cases in women in 2017 With 11913 deaths in 2015 breast cancer is the 1st largest cancer death in women 19 and the 3rd largest cancer death men and women included after lung and colorectal cancer At initial diagnosis at any stage approximately 31 of patients have regional lymph node involvement and 5 to 10 present metastatic involvement from the outset Progression to a metastatic form occurs in about 20 of cases The risk of metastatic evolution is variable depending on the histological subtype and is a major prognostic event directly impacting overall survival DOTATOC-68Ga PET scans allows in vivo evaluation of SST2 somatostatin receptor expression Its use is widely validated in clinical practice for the assessment of extension of neuroendocrine tumors It is also being used to evaluate the feasibility of SST2-targeted internal radiotherapy therapy with Litthera 177Lu-Oxodotreotide in patients with metastatic small intestine neuroendocrine tumours
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None